Genetic Technologies Future Growth

Future criteria checks 0/6

Se prevé que los beneficios deGenetic Technologies aumenten en 130.5% al año. Se prevé que el BPA de grow sea de 43.4% al año.

Key information

130.5%

Earnings growth rate

43.4%

EPS growth rate

Life Sciences earnings growth	16.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	12 Sep 2023

Recent future growth updates

No updates

Recent updates

Genetic acquires AffinityDNA to bolster direct-to-consumer business

Jul 14

Infinity Biologix launches Genetic Technologies' COVID-19 test

Jun 09

Genetic Technologies launches COVID-19 risk test through partnership with Infinity Biologix

Jun 01

Genetic Technologies’ COVID-19 risk test to be commercially available in U.S.

Apr 26

Genetic Technologies appoints new CEO; Shares are up 8%

Jan 04

Earnings and Revenue Growth Forecasts

NasdaqCM:GENE - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	10	-13	-8	-8	N/A
9/30/2023	10	-12	-9	-9	N/A
6/30/2023	10	-12	-10	-10	N/A
3/31/2023	11	-10	-9	-9	N/A
12/31/2022	11	-9	-8	-8	N/A
9/30/2022	10	-8	-7	-7	N/A
6/30/2022	9	-7	-6	-6	N/A
3/31/2022	7	-7	-6	-6	N/A
12/31/2021	5	-7	-7	-7	N/A
9/30/2021	3	-7	-7	-6	N/A
6/30/2021	1	-7	-7	-6	N/A
3/31/2021	2	-7	-7	-6	N/A
12/31/2020	0	-7	-7	-7	N/A
9/30/2020	0	-7	-6	-6	N/A
6/30/2020	1	-6	-6	-6	N/A
3/31/2020	0	-6	-6	-5	N/A
12/31/2019	0	-6	-5	-5	N/A
9/30/2019	0	-6	-6	-6	N/A
6/30/2019	0	-6	-6	-6	N/A
3/31/2019	0	-6	-6	-6	N/A
12/31/2018	0	-5	-6	-6	N/A
9/30/2018	0	-5	-6	-6	N/A
6/30/2018	0	-5	-6	-6	N/A
3/31/2018	0	-7	-6	-6	N/A
12/31/2017	0	-8	-7	-6	N/A
9/30/2017	0	-8	N/A	-7	N/A
6/30/2017	1	-8	N/A	-7	N/A
3/31/2017	1	-8	N/A	-7	N/A
12/31/2016	1	-8	N/A	-7	N/A
9/30/2016	1	-8	N/A	-7	N/A
6/30/2016	1	-8	N/A	-8	N/A
3/31/2016	1	-8	N/A	-8	N/A
12/31/2015	1	-8	N/A	-8	N/A
9/30/2015	2	-9	N/A	-9	N/A
6/30/2015	2	-9	N/A	-10	N/A
3/31/2015	3	-9	N/A	-11	N/A
12/31/2014	4	-10	N/A	-12	N/A
9/30/2014	4	-10	N/A	-11	N/A
6/30/2014	5	-10	N/A	-11	N/A
3/31/2014	4	-10	N/A	-10	N/A
12/31/2013	4	-11	N/A	-10	N/A
9/30/2013	4	-10	N/A	-9	N/A
6/30/2013	3	-9	N/A	-8	N/A

Analyst Future Growth Forecasts

Ingresos vs. tasa de ahorro: GENE se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios frente mercado: GENE se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: GENE se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de GENE crezcan más rápido que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de GENE crezcan a un ritmo superior a 20% al año.

Earnings per Share Growth Forecasts

Future Return on Equity

Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de GENE se prevé elevada dentro de 3 años.

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Genetic Technologies Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia

Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited Published in Plus One for Cvd & Type 2 Diabetes

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Genetic Technologies Limited (ASX:GTG) completed the acquisition of eCommerce Business and Distribution Rights of AffinityDNA from Affinity DNA Limited.

Genetic acquires AffinityDNA to bolster direct-to-consumer business

Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary

Genetic Technologies Limited Commences Initial Implementation of its geneType Risk Assessment Test at 16 Medical Practices Across the East Coast of Australia

Genetic Technologies Limited Announces the Completion of an Independently Developed and Validated Customisable Budget Impact Model

Genetic Technologies Limited (ASX:GTG) entered into an agreement to acquire eCommerce Business and Distribution Rights of AffinityDNA from Affinity Dna Limited for £0.555 million

Genetic Technologies Limited Announces GeneType Multi-Test Approves for Commercial Release

Genetic Technologies Limited (ASX:GTG) completed the acquisition of General Genetics Corporation from BelHealth Investment Fund, L.P. managed by BelHealth Investment Partners, LLC.

Infinity Biologix launches Genetic Technologies' COVID-19 test

Genetic Technologies Limited Confirms the Launch of GTG's Covid-19 Serious Disease Risk Test (`Covid-19 Risk Test') by US Based Infinity Biologix LLC

Genetic Technologies launches COVID-19 risk test through partnership with Infinity Biologix

Genetic Technologies Limited Provides COVID-19 Risk Test Launch Update

Genetic Technologies’ COVID-19 risk test to be commercially available in U.S.

Genetic Technologies Limited Signs 3-Year US Licence Agreement for COVID Risk Test

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $6.5625 million.

Genetic Technologies Limited Provides Update on Its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Genetic Technologies Limited Announces Management Changes

Genetic Technologies appoints new CEO; Shares are up 8%

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

Genetic Technologies Limited, Annual General Meeting, Dec 10, 2020

Genetic Technologies Limited to Report Q4, 2020 Results on Oct 30, 2020

Genetic Technologies Provides Update on COVID-19 Risk Test

Genetic Technologies Receives Delisting Notification Letter from Nasdaq

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $5.125 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies